RxDoctor Payments Data

Bryan Pagan Rivera, MD

Nephrology · San German, PRNPI 1760846497

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 54.0% of the total. Reporting peaked in 2023 at $1,882 and has fallen 78.4% since, to $407 in 2025.

$3,036in general payments, 2019–2025

Across 39 payments — averaging $77.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • AstraZeneca$585
  • GSK$214
  • Calliditas Therapeutics US Inc.$169
  • E.r. Squibb & Sons, L.L.C.$164
  • Johnson & Johnson$91
  • plus $174 from 4 others

What the payments were for

  • Consulting fees$1,64054%
  • Food & beverage$1,29743%
  • Education$993%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,036 in reported general payments places this provider in the 70th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,564
Medicare patients
29
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lanthanum Carbonate149$69,915
Sevelamer Carbonate408$48,961
FarxigaDapagliflozin Propanediol25$19,230
LokelmaSodium Zirconium Cyclosilicate13$9,138
Doxazosin Mesylate87$1,613
Calcium Acetate11$1,039
Nifedipine ErNifedipine36$814
Bumetanide30$636
Humulin RInsulin Regular, Human12$596
Hydralazine Hcl42$509
Losartan Potassium40$380
Irbesartan18$336
Metoprolol Succinate25$329
Atorvastatin Calcium38$315
Calcitriol34$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$585$28,36838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in San German

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →